MetLife Investment Management’s Evolent Health EVH Stock Holding History

MetLife Investment Management’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$83.9K	Sell	36,785 -17,558	-32%	-$55.7K	﹤0.01%	2607
2025 Q4	$217K	Sell	54,343 -9,786	-15%	-$54.4K	﹤0.01%	2230
2025 Q3	$543K	Sell	64,129 -5,700	-8%	-$55.3K	﹤0.01%	1766
2025 Q2	$786K	Hold	69,829	–	–	﹤0.01%	1445
2025 Q1	$661K	Sell	69,829 -1,086	-2%	-$11K	﹤0.01%	1568
2024 Q4	$798K	Buy	70,915 +4,185	+6%	+$73.5K	﹤0.01%	1536
2024 Q3	$1.89M	Hold	66,730	–	–	0.01%	1048
2024 Q2	$1.28M	Buy	66,730 +10,007	+18%	+$256K	0.01%	1216
2024 Q1	$1.86M	Sell	56,723 -1,345	-2%	-$42.9K	0.01%	982
2023 Q4	$1.92M	Hold	58,068	–	–	0.01%	964
2023 Q3	$1.58M	Hold	58,068	–	–	0.01%	1009
2023 Q2	$1.76M	Buy	58,068 +15,297	+36%	+$495K	0.01%	982
2023 Q1	$1.39M	Hold	42,771	–	–	0.01%	1063
2022 Q4	$1.2M	Sell	42,771 -1,401	-3%	-$40.2K	0.01%	1123
2022 Q3	$1.59M	Hold	44,172	–	–	0.01%	977
2022 Q2	$1.36M	Hold	44,172	–	–	0.01%	1063
2022 Q1	$1.43M	Buy	44,172 +15,143	+52%	+$396K	0.01%	1139
2021 Q4	$803K	Hold	29,029	–	–	0.01%	1224
2021 Q3	$900K	Hold	29,029	–	–	0.01%	1173
2021 Q2	$613K	Hold	29,029	–	–	0.01%	1448
2021 Q1	$586K	Sell	29,029 -2,037	-7%	-$38.7K	0.01%	1432
2020 Q4	$498K	Hold	31,066	–	–	﹤0.01%	1496
2020 Q3	$386K	Hold	31,066	–	–	﹤0.01%	1507
2020 Q2	$221K	Hold	31,066	–	–	﹤0.01%	1851
2020 Q1	$169K	Hold	31,066	–	–	﹤0.01%	1790
2019 Q4	$281K	Hold	31,066	–	–	﹤0.01%	1792
2019 Q3	$223K	Hold	31,066	–	–	﹤0.01%	1879
2019 Q2	$247K	Hold	31,066	–	–	﹤0.01%	1906
2019 Q1	$391K	Hold	31,066	–	–	﹤0.01%	1601
2018 Q4	$620K	Hold	31,066	–	–	0.01%	1234
2018 Q3	$882K	Hold	31,066	–	–	0.01%	1195
2018 Q2	$654K	Buy	31,066 +6,178	+25%	+$117K	0.01%	1249
2018 Q1	$355K	Hold	24,888	–	–	﹤0.01%	1584
2017 Q4	$306K	Buy	+24,888	New	+$351K	﹤0.01%	1698

Other funds holding EVH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's EVH Position: Q1 2026 in Review

MetLife Investment Management reduced its Evolent Health (EVH) stake by 32% in Q1 2026, selling an estimated $55.7K and leaving 36,785 shares worth $83.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2607.

MetLife Investment Management first reported a position in EVH in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.92M in Q4 2023. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

MetLife Investment Management held 36,785 shares of Evolent Health worth $83.9K as of Q1 2026.
MetLife Investment Management sold 17,558 Evolent Health shares in Q1 2026, an estimated $55.7K.
Evolent Health made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2607 holding.
MetLife Investment Management first reported a position in Evolent Health in Q4 2017 and has held it in 34 quarters since.
MetLife Investment Management's Evolent Health position peaked at $1.92M in Q4 2023.
191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.